GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PAVmed Inc (NAS:PAVM) » Definitions » Piotroski F-Score

PAVmed (PAVmed) Piotroski F-Score : 3 (As of May. 01, 2024)


View and export this data going back to 2016. Start your Free Trial

What is PAVmed Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PAVmed has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for PAVmed's Piotroski F-Score or its related term are showing as below:

PAVM' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 6
Current: 3

During the past 10 years, the highest Piotroski F-Score of PAVmed was 6. The lowest was 2. And the median was 3.


PAVmed Piotroski F-Score Historical Data

The historical data trend for PAVmed's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PAVmed Piotroski F-Score Chart

PAVmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 6.00 2.00 3.00

PAVmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 2.00 2.00 4.00 3.00

Competitive Comparison of PAVmed's Piotroski F-Score

For the Medical Devices subindustry, PAVmed's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PAVmed's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, PAVmed's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where PAVmed's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -17.931 + -14.537 + -17.671 + -14.036 = $-64.18 Mil.
Cash Flow from Operations was -16.287 + -12.786 + -11.089 + -11.874 = $-52.04 Mil.
Revenue was 0.446 + 0.166 + 0.791 + 1.049 = $2.45 Mil.
Gross Profit was -0.9 + -1.519 + -0.988 + -0.562 = $-3.97 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(53.98 + 65.286 + 53.683 + 42.02 + 33.119) / 5 = $49.6176 Mil.
Total Assets at the begining of this year (Dec22) was $53.98 Mil.
Long-Term Debt & Capital Lease Obligation was $2.96 Mil.
Total Current Assets was $24.50 Mil.
Total Current Liabilities was $54.18 Mil.
Net Income was -16.872 + -25.525 + -26.126 + -20.46 = $-88.98 Mil.

Revenue was 0.189 + 0 + 0.076 + 0.112 = $0.38 Mil.
Gross Profit was -0.18 + 0 + -1.55 + -1.506 = $-3.24 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(86.976 + 84.334 + 82.454 + 72.465 + 53.98) / 5 = $76.0418 Mil.
Total Assets at the begining of last year (Dec21) was $86.98 Mil.
Long-Term Debt & Capital Lease Obligation was $1.85 Mil.
Total Current Assets was $43.93 Mil.
Total Current Liabilities was $41.20 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PAVmed's current Net Income (TTM) was -64.18. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

PAVmed's current Cash Flow from Operations (TTM) was -52.04. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-64.175/53.98
=-1.18886625

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-88.983/86.976
=-1.02307533

PAVmed's return on assets of this year was -1.18886625. PAVmed's return on assets of last year was -1.02307533. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

PAVmed's current Net Income (TTM) was -64.18. PAVmed's current Cash Flow from Operations (TTM) was -52.04. ==> -52.04 > -64.18 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=2.96/49.6176
=0.05965625

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1.846/76.0418
=0.02427612

PAVmed's gearing of this year was 0.05965625. PAVmed's gearing of last year was 0.02427612. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=24.498/54.177
=0.45218451

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=43.926/41.2
=1.06616505

PAVmed's current ratio of this year was 0.45218451. PAVmed's current ratio of last year was 1.06616505. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

PAVmed's number of shares in issue this year was 8.023. PAVmed's number of shares in issue last year was 6.209. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-3.969/2.452
=-1.61867863

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-3.236/0.377
=-8.58355438

PAVmed's gross margin of this year was -1.61867863. PAVmed's gross margin of last year was -8.58355438. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=2.452/53.98
=0.04542423

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=0.377/86.976
=0.00433453

PAVmed's asset turnover of this year was 0.04542423. PAVmed's asset turnover of last year was 0.00433453. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

PAVmed has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

PAVmed  (NAS:PAVM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


PAVmed Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of PAVmed's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PAVmed (PAVmed) Business Description

Traded in Other Exchanges
N/A
Address
360 Madison Avenue, 25th Floor, New York, NY, USA, 10017
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard and the Veris Cancer Care Platform.
Executives
Michael J Glennon director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Michael Adam Gordon officer: General Counsel ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Shaun O'neil officer: Chief Operating Officer ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
James L Cox director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Debra White director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Ronald M Sparks director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Brian J. Deguzman officer: Chief Medical Officer 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170
Dennis M Mcgrath officer: President & CFO C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Lishan Aklog director, 10 percent owner, officer: Chairman and CEO 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10171
Joan B Harvey director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Timothy E Baxter director ONE GRAND CENTRAL PLACE, SUITE 4600, NEW YORK NY 10165
Matthew Sirovich 10 percent owner C/O SCOPIA MANAGEMENT INC, 450 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10123
Ira Scott Greenspan director 888 SEVENTH AVENUE, 9TH FLOOR, NEW YORK NY 10106
David S. Battleman director C/O TRUENORTH LIFESCIENCES, 348 WEST 57TH STREET, #226, NEW YORK NY 10019
Joshua R Lamstein director 420 LEXINGTON AVENUE, SUITE 300, NEW YORK NY 10170